Kiora Pharmaceuticals’ (KPRX) Buy Rating Reiterated at HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 231.13% from the company’s current price.

Kiora Pharmaceuticals Stock Performance

KPRX opened at $3.02 on Friday. The business’s 50-day simple moving average is $3.48 and its 200-day simple moving average is $3.48. The stock has a market capitalization of $9.06 million, a P/E ratio of 2.90 and a beta of -0.46. Kiora Pharmaceuticals has a one year low of $2.91 and a one year high of $6.48.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its earnings results on Tuesday, March 25th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.40). The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.75 million. On average, equities research analysts forecast that Kiora Pharmaceuticals will post 1.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC boosted its position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned about 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent SEC filing. 76.97% of the stock is owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.